Novartis | NOVN - Ebitda





Ebitda Veränderung Datum
AbbVie USD 6.91B 3.22B 2026-06
Alcon AG USD 728M 72M 2026-09
Almirall EUR 80.45M 33.61M 2026-06
Amgen USD 5.8B 1.25B 2026-09
AstraZeneca USD 7.46B 2.3B 2026-09
Autolus Therapeutics Ltd USD -56.8M 13.28M 2026-03
Bayer EUR 1.62B 529M 2026-09
Biogen USD 450.8M 198.9M 2026-06
Bristol-Myers Squibb USD 3.48B 1.6B 2026-09
Eli Lilly USD 9.46B 3.54B 2026-09
Fresenius EUR 912M 76M 2026-09
Fresenius Medical Care EUR 817M 26.66M 2026-09
Genmab DKK 401M 186M 2026-06
Gilead Sciences USD -9.31B 12.82B 2026-06
GlaxoSmithKline GBP 3.51B 734M 2026-06
GRIFOLS EUR 505M 32M 2026-09
Hikma Pharmaceutical USD 369M 84M 2024-12
J&J USD 8.99B 721M 2026-06
Lakefront Biotherapeutics EUR -63.7M 624.2M 2026-03
Lonza CHF 1.01B 54M 2025-12
Merck EUR 1.68B 82.6M 2026-09
Merck USD 1.42B 2.97B 2026-06
Novartis USD 8.62B 2.14B 2026-09
Novartis USD 5.36B 45M 2026-09
Novo Nordisk DKK 37.36B 2.64B 2026-06
Orion EUR 225.5M 33.6M 2026-09
Pfizer USD 6.36B 350M 2026-09
Philips EUR 772M 138M 2026-09
Recordati EUR 260.9M 4.3M 2026-09
Regeneron Pharmaceuticals USD 1.66B 695.2M 2026-06
Roche Holding CHF 13.43B 744M 2026-06
Sanofi EUR 5.79B 2.1B 2026-09
UCB EUR 1.6B 570M 2025-12